Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026
Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026
Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Fineline Cube Jan 13, 2026
Company Drug

Summit Therapeutics Submits Ivonescimab BLA to FDA for EGFR‑Mutated NSCLC Post Third‑Gen TKI

Fineline Cube Jan 13, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Deals

Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions

Fineline Cube Jun 21, 2022

Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...

Company Deals

Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development

Fineline Cube Jun 21, 2022

China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...

Company Medical Device

Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits

Fineline Cube Jun 21, 2022

China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...

Company Drug

SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA

Fineline Cube Jun 21, 2022

China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...

Company Deals

Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round

Fineline Cube Jun 21, 2022

Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...

Company Deals R&D

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

Fineline Cube Jun 20, 2022

Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...

Company Drug

Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma

Fineline Cube Jun 20, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...

Policy / Regulatory

China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules

Fineline Cube Jun 20, 2022

China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related...

Company Deals

Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...

Company Medical Device

Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis

Fineline Cube Jun 20, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect...

Company Deals

Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion

Fineline Cube Jun 20, 2022

Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...

Company Drug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Fineline Cube Jun 20, 2022

China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...

Policy / Regulatory

CDE Releases 58th and 59th Batches of Chemical Generic Reference Preparations

Fineline Cube Jun 20, 2022

The Center for Drug Evaluation (CDE) has released the 58th and 59th batches of chemical...

Company Deals

Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...

Company Drug

Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14

Fineline Cube Jun 20, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study

Fineline Cube Jun 20, 2022

China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...

Company Deals

Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial

Fineline Cube Jun 20, 2022

Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from...

Company Deals

Hangzhou Tongee Medical Closes RMB 100 Million Series B Round for Gastric Bypass Stent

Fineline Cube Jun 19, 2022

Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments,...

Policy / Regulatory

Scotland Reports First Case of ASHep-UA in Children, WHO Issues Guidelines

Fineline Cube Jun 19, 2022

Scotland recorded its first case of acute severe hepatitis of unknown etiology in children (ASHep-UA)...

Company Drug R&D

Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial

Fineline Cube Jun 19, 2022

Walvax Biotechnology Co., Ltd’s (SHE: 300142) mRNA vaccine against SARS-CoV-2, named AWcorna, has reached the...

Posts pagination

1 … 602 603 604 … 608

Recent updates

  • Summit Therapeutics Submits Ivonescimab BLA to FDA for EGFR‑Mutated NSCLC Post Third‑Gen TKI
  • China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs
  • RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones
  • Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China
  • Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Summit Therapeutics Submits Ivonescimab BLA to FDA for EGFR‑Mutated NSCLC Post Third‑Gen TKI

Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Company Medical Device

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.